Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.

The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.

It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia.

The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.